In:
Current Pharmaceutical Design, Bentham Science Publishers Ltd., Vol. 24, No. 1 ( 2018-03-22), p. 78-83
Abstract:
T-cell therapy using genetically engineered T cells modified with either T cell receptor or chimeric
antigen receptor holds great promise for cancer immunotherapy. The concerns about its toxicities still remain despite recent successes in clinical trials. Temporal and spatial control of the engineered therapeutic T cells may
improve the safety profile of these treatment regimens. To achieve these goals, numerous approaches have been tested and utilized including the incorporation of a suicide gene, the switch-mediated activation, the combinatorial
antigen recognition, etc. This review will summarize the toxicities caused by engineered T cells and novel strategies to overcome them.
Type of Medium:
Online Resource
ISSN:
1381-6128
DOI:
10.2174/1381612824666171227222624
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2018
SSG:
15,3
